Copyright © 2012 Varvara Valotassiou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. D. C. Weber, K. O. Lovblad, and L. Rogers, “New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright,” Current Opinion in Neurology, vol. 23, no. 6, pp. 563–570, 2010. View at Publisher · View at Google Scholar · View at Scopus
2. C. Mawrin and A. Perry, “Pathological classification and molecular genetics of meningiomas,” Journal of Neuro-Oncology, vol. 99, no. 3, pp. 379–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
3. E. B. Claus, M. L. Bondy, J. M. Schildkraut, J. L. Wiemels, M. Wrensch, and P. M. Black, “Epidemiology of intracranial meningioma,” Neurosurgery, vol. 57, no. 6, pp. 1088–1095, 2005. View at Publisher · View at Google Scholar · View at Scopus
4. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
5. A. Perry, D. N. Louis, B. W. Scheithauer, H. Budka, and A. von Deimling, “Meningiomas,” in World Health Organization Classification of Tumours of the Central Nervous System, D. N. Louis, H. Ohgaki, O. D. Wiestler, and W. K. Cavenee, Eds., vol. 1, pp. 164–172, IARC Press, Lyon, France, 4th edition, 2007. View at Google Scholar
6. E. Lusis and D. H. Gutmann, “Meningioma: an update,” Current Opinion in Neurology, vol. 17, no. 6, pp. 687–692, 2004. View at Publisher · View at Google Scholar · View at Scopus
7. C. Marosi, M. Hassler, K. Roessler et al., “Meningioma,” Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 153–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
8. D. Simpson, “The recurrence of intracranial meningiomas after surgical treatment,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 20, no. 1, pp. 22–39, 1957. View at Google Scholar · View at Scopus
9. J. Jääskelainen, “Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis,” Surgical Neurology, vol. 26, no. 5, pp. 461–469, 1986. View at Google Scholar · View at Scopus
10. D. Raghavan, M. L. Brecher, D. H. Johnson, N. J. Meropol, P. L. Moots, and P. G. Rose, Textbook of Uncommon Cancer, John Wiley & Sons, New York, NY, USA, 1999.
11. F. Kayaselcuk, S. Zorludemir, N. Bal, B. Erdogan, S. Erdogan, and T. Erman, “The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome,” Journal of Neuro-Oncology, vol. 67, no. 1-2, pp. 209–214, 2004. View at Publisher · View at Google Scholar · View at Scopus
12. K. A. Jaeckle, “Neuroimaging for central nervous system tumors,” Seminars in Oncology, vol. 18, no. 2, pp. 150–157, 1991. View at Google Scholar · View at Scopus
13. H. L. Atkins, T. F. Budinger, and E. Lebowitz, “Thallium 201 for medical use. Part 3: human distribution and physical imaging properties,” Journal of Nuclear Medicine, vol. 18, no. 2, pp. 133–140, 1977. View at Google Scholar · View at Scopus
14. N. Tonami, “Thallium-201 SPECT in the evaluation of gliomas,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2089–2090, 1993. View at Google Scholar · View at Scopus
15. S. Jinnouchi, H. Hoshi, T. Ohnishi et al., “Thallium-201 SPECT for predicting histological types of meningiomas,” Journal of Nuclear Medicine, vol. 34, no. 12, pp. 2091–2094, 1993. View at Google Scholar · View at Scopus
16. E. Tedeschi, A. Soricelli, A. Brunetti et al., “Different thallium-201 single-photon emission tomographic patterns in benign and aggressive meningiomas,” European Journal of Nuclear Medicine, vol. 23, no. 11, pp. 1478–1484, 1996. View at Publisher · View at Google Scholar · View at Scopus
17. K. Kinuya, M. Ohashi, S. Itoh et al., “Thallium-201 brain SPECT to diagnose aggressiveness of meningiomas,” Annals of Nuclear Medicine, vol. 17, no. 6, pp. 463–467, 2003. View at Google Scholar · View at Scopus
18. T. Takeda, T. Nakano, K. Asano, N. Shimamura, and H. Ohkuma, “Usefulness of thallium-201 SPECT in the evaluation of tumor natures in intracranial meningiomas,” Neuroradiology, vol. 53, no. 11, pp. 867–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
19. B. Bagni, L. Pinna, R. Tamarozzi et al., “SPET imaging of intracranial tumours with 99Tcm-sestamibi,” Nuclear Medicine Communications, vol. 16, no. 4, pp. 258–264, 1995. View at Google Scholar · View at Scopus
20. J. L. Moretti, N. Hauet, M. Caglar, O. Rebillard, and Z. Burak, “To use MIBI or not to use MIBI? That is the question when assessing tumour cells,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 7, pp. 836–842, 2005. View at Publisher · View at Google Scholar · View at Scopus
21. N. S. Petrovic, D. Grujicic, V. M. Artiko et al., “Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile,” Nuclear Medicine Communications, vol. 31, no. 11, pp. 962–973, 2010. View at Publisher · View at Google Scholar · View at Scopus
22. I. Ak, Z. Gulbas, F. Altinel, and E. Vardareli, “Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors,” Clinical Nuclear Medicine, vol. 28, no. 1, pp. 29–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
23. F. Cesani, R. Ernst, G. Storey, and J. Villanueva-Meyer, “Multicentric meningioma evaluation with Tc-99m MIBI SPECT, CT, and MRI,” Clinical Nuclear Medicine, vol. 20, no. 6, pp. 557–558, 1995. View at Publisher · View at Google Scholar · View at Scopus
24. K. Kunishio, K. Morisaki, Y. Matsumoto, S. Nagao, and Y. Nishiyama, “Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression, encoded by the multidrug resistance gene-1 messenger ribonucleic acid, in intracranial meningiomas,” Neurologia Medico-Chirurgica, vol. 43, no. 12, pp. 573–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
25. A. Spanu, F. Ginesu, P. Pirina et al., “The usefulness of 99mTc-tetrofosmin SPECT in the detection of intrathoracic malignant lesions,” International Journal of Oncology, vol. 22, no. 3, pp. 639–649, 2003. View at Google Scholar · View at Scopus
26. J. Y. Choi, S. E. Kim, H. J. Shin, B. T. Kim, and J. H. Kim, “Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-flourodeoxyglucose,” Journal of Neuro-Oncology, vol. 46, no. 1, pp. 63–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
27. A. D. Fotopoulos, G. A. Alexiou, A. Goussia et al., “99mTc-Tetrofosmin brain SPECT in the assessment of meningiomas—correlation with histological grade and proliferation index,” Journal of Neuro-Oncology, vol. 89, no. 2, pp. 225–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
28. G. A. Alexiou, G. Vartholomatos, S. Tsiouris et al., “Evaluation of meningioma aggressiveness by 99mTc-Tetrofosmin SPECT,” Clinical Neurology and Neurosurgery, vol. 110, no. 7, pp. 645–648, 2008. View at Publisher · View at Google Scholar · View at Scopus
29. K. H. Bohuslavizki, “Somatostatin receptor imaging: current status and future perspectives,” Journal of Nuclear Medicine, vol. 42, no. 7, pp. 1057–1058, 2001. View at Google Scholar · View at Scopus
30. J. Epelbaum, “Somatostatin in the central nervous system: physiology and pathological modifications,” Progress in Neurobiology, vol. 27, no. 1, pp. 63–100, 1986. View at Google Scholar · View at Scopus
31. J. C. Reubi, L. Kvols, E. Krenning, and S. W. J. Lamberts, “Distribution of somatostatin receptors in normal and tumor tissue,” Metabolism, vol. 39, supplement 2, no. 9, pp. 78–81, 1990. View at Publisher · View at Google Scholar · View at Scopus
32. Y. Yamada, S. R. Post, K. Wang, H. S. Tager, G. I. Bell, and S. Seino, “Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 1, pp. 251–255, 1992. View at Google Scholar · View at Scopus
33. G. I. Bell and T. Reisine, “Molecular biology of somatostatin receptors,” Trends in Neurosciences, vol. 16, no. 1, pp. 34–38, 1993. View at Google Scholar · View at Scopus
34. M. John, W. Meyerhof, D. Richter et al., “Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2,” Gut, vol. 38, no. 1, pp. 33–39, 1996. View at Google Scholar · View at Scopus
35. J. Held-Feindt, B. Krisch, and R. Mentlein, “Molecular analysis of the somatostatin receptor subtype 2 in human glioma cells,” Molecular Brain Research, vol. 64, no. 1, pp. 101–107, 1999. View at Publisher · View at Google Scholar · View at Scopus
36. M. Papotti, S. Croce, L. Macrì et al., “Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung,” Diagnostic Molecular Pathology, vol. 9, no. 1, pp. 47–57, 2000. View at Publisher · View at Google Scholar · View at Scopus
37. M. Vanetti, G. Vogt, and V. Hollt, “The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization,” The FEBS Letters, vol. 331, no. 3, pp. 260–266, 1993. View at Publisher · View at Google Scholar · View at Scopus
38. J. C. Reubi, R. Maurer, and S. W. J. Lamberts, “Somatostatin binding sites in human leptomeninx,” Neuroscience Letters, vol. 70, no. 2, pp. 183–186, 1986. View at Google Scholar · View at Scopus
39. J. C. Reubi, R. Maurer, J. G. M. Klijn, et al., “High incidence of somatostatin receptors in human meningiomas: biochemical characterization,” Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 2, pp. 433–438, 1986. View at Google Scholar · View at Scopus
40. W. H. Bakker, R. Albert, C. Bruns et al., “[¹¹¹In-DTPA-D-Phe¹]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation,” Life Sciences, vol. 49, no. 22, pp. 1583–1591, 1991. View at Publisher · View at Google Scholar · View at Scopus
41. Y. C. Patel and C. B. Srikant, “Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5),” Endocrinology, vol. 135, no. 6, pp. 2814–2817, 1994. View at Publisher · View at Google Scholar · View at Scopus
42. S. Schulz, S. U. Pauli, S. Schulz et al., “Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype ${\text{sst}}_{2\text{A}}$,” Clinical Cancer Research, vol. 6, no. 5, pp. 1865–1874, 2000. View at Google Scholar · View at Scopus
43. A. R. Haldemann, H. Rösler, A. Barth et al., “Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability,” Journal of Nuclear Medicine, vol. 36, no. 3, pp. 403–410, 1995. View at Google Scholar · View at Scopus
44. N. Nathoo, K. Ugokwe, A. S. Chang et al., “The role of ¹¹¹indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas,” Journal of Neuro-Oncology, vol. 81, no. 2, pp. 167–174, 2007. View at Publisher · View at Google Scholar · View at Scopus
45. A. Dutour, U. Kumar, R. Panetta et al., “Expression of somatostatin receptor subtypes in human brain tumors,” International Journal of Cancer, vol. 76, no. 5, pp. 620–627, 1998. View at Publisher · View at Google Scholar · View at Scopus
46. M. Schmidt, K. Scheidhauer, C. Luyken et al., “Somatostatin receptor imaging in intracranial tumours,” European Journal of Nuclear Medicine, vol. 25, no. 7, pp. 675–686, 1998. View at Publisher · View at Google Scholar · View at Scopus
47. G. Hildebrandt, K. Scheidhauer, C. Luyken et al., “High sensitivity of the in vivo detection of somatostatin receptors by ¹¹¹Indium (DTPA-octreotide)-scintigraphy in meningioma patients,” Acta Neurochirurgica, vol. 126, no. 2–4, pp. 63–71, 1994. View at Google Scholar · View at Scopus
48. K. Scheidhauer, G. Hildebrandt, C. Luyken, K. Schomäcker, N. Klug, and H. Schicha, “Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences,” Hormone and Metabolic Research, Supplement, no. 27, pp. 59–62, 1993. View at Google Scholar · View at Scopus
49. C. Luyken, G. Hildebrandt, K. Scheidhauer, B. Krisch, H. Schicha, and N. Klug, “¹¹¹Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas,” Acta Neurochirurgica, vol. 127, no. 1-2, pp. 60–64, 1994. View at Google Scholar · View at Scopus
50. E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993. View at Google Scholar · View at Scopus
51. K. H. Bohuslavizki, W. Brenner, W. E. K. Braunsdorf et al., “Somatostatin receptor scintigraphy in the differential diagnosis of meningioma,” Nuclear Medicine Communications, vol. 17, no. 4, pp. 302–310, 1996. View at Google Scholar · View at Scopus
52. J. C. Reubi, W. Lang, R. Maurer, J. W. Koper, and S. W. J. Lamberts, “Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system,” Cancer Research, vol. 47, no. 21, pp. 5758–5764, 1987. View at Google Scholar · View at Scopus
53. A. Leondi, V. Valotassiou, J. Koutsikos, S. Tsiouris, E. Mainta, and C. Zerva, “Multiple meningiomas,” Clinical Nuclear Medicine, vol. 30, no. 5, pp. 361–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
54. P. Saeed, M. W. T. Tanck, N. Freling, L. Baldeschi, M. P. Mourits, and R. J. Bennink, “Somatostatin receptor scintigraphy for optic nerve sheath meningiomas,” Ophthalmology, vol. 116, no. 8, pp. 1581–1586, 2009. View at Publisher · View at Google Scholar · View at Scopus
55. S. Klutmann, K. H. Bohuslavizki, W. Brenner et al., “Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma,” Journal of Nuclear Medicine, vol. 39, no. 11, pp. 1913–1917, 1998. View at Google Scholar · View at Scopus
56. P. M. Black, “Brain tumors. Part 1,” The New England Journal of Medicine, vol. 324, no. 21, pp. 1471–1476, 1991. View at Google Scholar · View at Scopus
57. P. M. Black, “Brain tumors. Part 2,” The New England Journal of Medicine, vol. 324, no. 22, pp. 1555–1564, 1991. View at Google Scholar · View at Scopus
58. F. deMonte, “Surgery of skull base tumors,” Current Opinion in Oncology, vol. 7, no. 3, pp. 201–206, 1995. View at Google Scholar · View at Scopus
59. V. Barresi, C. Alafaci, F. Salpietro, and G. Tuccari, “Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density?” Oncology Reports, vol. 20, no. 3, pp. 485–492, 2008. View at Publisher · View at Google Scholar · View at Scopus
60. J. E. Bhim, H. Handmakcr, and N. A. Rinne, “The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules,” Chest, vol. 115, no. 1, pp. 224–232, 1999. View at Publisher · View at Google Scholar · View at Scopus
61. I. Virgolini, M. Leimer, H. Handmaker et al., “Somatostatin receptor subtype specificity and in viva binding of a novel tumor tracer, 99mTc-P829,” Cancer Research, vol. 58, no. 9, pp. 1850–1859, 1998. View at Google Scholar · View at Scopus
62. I. Virgolini, T. Traub, C. Novotny et al., “New trends in peptide receptor radioligands,” Quarterly Journal of Nuclear Medicine, vol. 45, no. 2, pp. 153–159, 2001. View at Google Scholar · View at Scopus
63. Committee for Proprietary Medicinal Products (CPMP), European Public Assessment Report 2065: Scientific Discussion of Depreotide (NeoSPECT): Clinical Pharmacology. London: The European Agency for the Evaluation of Medicinal Products (EAMA), pp. 11–14, 2000.
64. E. P. Krenning, W. H. Bakker, P. P. M. Kooij et al., “Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide,” Journal of Nuclear Medicine, vol. 33, no. 5, pp. 652–658, 1992. View at Google Scholar · View at Scopus
65. D. Hellwig, S. Samnick, J. Reif et al., “Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma,” Clinical Nuclear Medicine, vol. 27, no. 11, pp. 781–784, 2002. View at Publisher · View at Google Scholar · View at Scopus
66. G. di Chiro, J. Hatazawa, D. A. Katz, H. V. Rizzoli, and D. J. de Michele, “Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study,” Radiology, vol. 164, no. 2, pp. 521–526, 1987. View at Google Scholar
67. A. Sabet, H. Ahmadzadehfar, U. Herrlinger, W. Wilinek, H. J. Biersack, and S. Ezziddin, “Successful radiopeptide targeting of metastatic anaplastic meningioma: case report,” Radiation Oncology, vol. 6, no. 1, article 94, 2011. View at Publisher · View at Google Scholar
68. J. W. Lee, K. W. Kang, S. H. Park et al., “¹⁸F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 10, pp. 1574–1582, 2009. View at Publisher · View at Google Scholar · View at Scopus
69. U. Cremerius, E. Striepecke, W. Henn et al., “¹⁸FDG-PET in intracranial meningiomas versus grading, proliferation index, cellular density and cytogenetical analysis,” NuklearMedizin, vol. 33, no. 4, pp. 144–149, 1994. View at Google Scholar · View at Scopus
70. U. Cremerius, R. Bares, J. Weis et al., “Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET,” Journal of Nuclear Medicine, vol. 38, no. 1, pp. 26–30, 1997. View at Google Scholar · View at Scopus
71. D. Delbeke, C. Meyerowitz, R. L. Lapidus et al., “Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET,” Radiology, vol. 195, no. 1, pp. 47–52, 1995. View at Google Scholar · View at Scopus
72. R. S. Liu, C. P. Chang, W. Y. Guo et al., “1-¹¹C-acetate versus ¹⁸F-FDG PET in detection of meningioma and monitoring the effect of γ-knife radiosurgery,” Journal of Nuclear Medicine, vol. 51, no. 6, pp. 883–891, 2010. View at Publisher · View at Google Scholar · View at Scopus
73. T. S. Lee, S. H. Ahn, B. S. Moon et al., “Comparison of ¹⁸F-FDG, ¹⁸F-FET and ¹⁸F-FLT for differentiation between tumor and inflammation in rats,” Nuclear Medicine and Biology, vol. 36, no. 6, pp. 681–686, 2009. View at Publisher · View at Google Scholar · View at Scopus
74. P. Caroli, C. Nanni, D. Rubello, A. Alavi, and S. Fanti, “Non-FDG PET in the practice of oncology,” Indian Journal of Cancer, vol. 47, no. 2, pp. 120–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
75. W. Vaalburg, H. H. Coenen, C. Crouzel et al., “Amino acids for the measurement of protein synthesis in vivo by PET,” International Journal of Radiation Applications and Instrumentation B, vol. 19, no. 2, pp. 227–237, 1992. View at Publisher · View at Google Scholar · View at Scopus
76. O. Gudjonsson, E. Blomquist, A. Lilja, H. Ericson, M. Bergström, and G. Nyberg, “Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of ¹¹C-L-methionine PET,” European Journal of Nuclear Medicine, vol. 27, no. 12, pp. 1793–1799, 2000. View at Publisher · View at Google Scholar · View at Scopus
77. A. L. Grosu, W. A. Weber, S. T. Astner et al., “¹¹C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 66, no. 2, pp. 339–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
78. G. Nyberg, M. Bergström, P. Enblad, A. Lilja, C. Muhr, and B. Långström, “PET-methionine of skull base neuromas and meningiomas,” Acta Oto-Laryngologica, vol. 117, no. 4, pp. 482–489, 1997. View at Google Scholar · View at Scopus
79. T. Ogawa, A. Inugami, J. Hatazawa et al., “Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-¹¹C-methionine,” American Journal of Neuroradiology, vol. 17, no. 2, pp. 345–353, 1996. View at Google Scholar · View at Scopus
80. S. T. Astner, M. Dobrei-Ciuchendea, M. Essler et al., “Effect of ¹¹C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas,” International Journal of Radiation Oncology, Biology, Physics, vol. 72, no. 4, pp. 1161–1167, 2008. View at Publisher · View at Google Scholar · View at Scopus
81. H. Arita, M. Kinoshita, Y. Okita, et al., “Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography,” Journal of Neuro-Oncology, vol. 107, no. 2, pp. 379–386, 2012. View at Google Scholar
82. T. Iuchi, Y. Iwadate, H. Namba et al., “Glucose and methionine uptake and proliferative activity in meningiomas,” Neurological Research, vol. 21, no. 7, pp. 640–644, 1999. View at Google Scholar · View at Scopus
83. I. Rutten, J. E. Cabay, N. Withofs et al., “PET/CT of skull base meningiomas using 2-¹⁸F-fluoro-L-tyrosine: initial report,” Journal of Nuclear Medicine, vol. 48, no. 5, pp. 720–725, 2007. View at Publisher · View at Google Scholar · View at Scopus
84. R. C. Murphy, A. Kawashima, and P. J. Peller, “The utility of ¹¹C-choline PET/CT for imaging prostate cancer: a pictorial guide,” American Journal of Roentgenology, vol. 196, no. 6, pp. 1390–1398, 2011. View at Publisher · View at Google Scholar
85. T. Hara, N. Kosaka, N. Shinoura, and T. Kondo, “PET imaging of brain tumor with [methyl-¹¹C]choline,” Journal of Nuclear Medicine, vol. 38, no. 6, pp. 842–847, 1997. View at Google Scholar · View at Scopus
86. R. Buhl, A. Nabavi, S. Wolff et al., “MR spectroscopy in patients with intracranial meningiomas,” Neurological Research, vol. 29, no. 1, pp. 43–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
87. F. Fallanca, G. Giovacchini, M. Picchio, V. Bettinardi, C. Messa, and F. Fazio, “Incidental detection by [¹¹C]choline PET/CT of meningiomas in prostate cancer patients,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 4, pp. 417–421, 2009. View at Google Scholar · View at Scopus
88. G. Giovacchini, F. Fallanca, C. Landoni et al., “C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience,” Clinical Nuclear Medicine, vol. 34, no. 1, pp. 7–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
89. E. Y. Yu, M. Muzi, J. A. Hackenbracht et al., “C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy,” Clinical Nuclear Medicine, vol. 36, no. 3, pp. 192–198, 2011. View at Publisher · View at Google Scholar
90. N. Salem, Y. Kuang, D. Corn, et al., “[(Methyl)1-¹¹C]-acetate metabolism in hepatocellular carcinoma,” Molecular Imaging and Biology, vol. 13, no. 1, pp. 140–151, 2011. View at Google Scholar
91. H. Nomori, H. Shibata, K. Uno et al., “¹¹C-acetate can be used in place of ¹⁸f-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma,” Journal of Thoracic Oncology, vol. 3, no. 12, pp. 1427–1432, 2008. View at Publisher · View at Google Scholar · View at Scopus
92. R. S. Liu, C. P. Chang, L. S. Chu et al., “PET imaging of brain astrocytoma with 1-¹¹C-acetate,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 4, pp. 420–427, 2006. View at Publisher · View at Google Scholar · View at Scopus
93. S. H. Yeh, R. S. Liu, L. C. Wu, S. H. Yen, C. W. Chang, and K. Y. Chen, “¹¹C-acetate clearance in nasopharyngeal carcinoma,” Nuclear Medicine Communications, vol. 20, no. 2, pp. 131–134, 1999. View at Google Scholar · View at Scopus
94. N. Oyama, H. Akino, H. Kanamaru et al., “¹¹C-acetate PET imaging of prostate cancer,” Journal of Nuclear Medicine, vol. 43, no. 2, pp. 181–186, 2002. View at Google Scholar · View at Scopus
95. G. A. Dienel, D. Popp, P. D. Drew, K. Ball, A. Krisht, and N. F. Cruz, “Preferential labeling of glial and meningial brain tumors with [2-¹⁴C]acetate,” Journal of Nuclear Medicine, vol. 42, no. 8, pp. 1243–1250, 2001. View at Google Scholar · View at Scopus
96. K. G. Go, “The normal and pathological physiology of brain water,” Advances and Technical Standards in Neurosurgery, vol. 23, pp. 47–142, 1997. View at Google Scholar · View at Scopus
97. Z. Xiangsong, L. Changhong, C. Weian, and Z. Dong, “PET imaging of cerebral astrocytoma with ¹³N-ammonia,” Journal of Neuro-Oncology, vol. 78, no. 2, pp. 145–151, 2006. View at Publisher · View at Google Scholar · View at Scopus
98. Z. Xiangsong and C. Weian, “Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with ¹³N-NH₃ PET,” Journal of Neuro-Oncology, vol. 82, no. 3, pp. 305–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
99. Z. Xiangsong, S. Xingchong, Y. Chang, W. Xiaoyan, and C. Zhifeng, “¹³N-NH₃ versus F-18 FDG in detection of intracranial meningioma: initial report,” Clinical Nuclear Medicine, vol. 36, no. 11, pp. 1003–1006, 2011. View at Publisher · View at Google Scholar
100. A. Heppeler, S. Froidevaux, H. R. Mäcke et al., “Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy,” Chemistry A, vol. 5, no. 7, pp. 1974–1981, 1999. View at Google Scholar · View at Scopus
101. J. C. Reubi, J. C. Schär, B. Waser et al., “Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use,” European Journal of Nuclear Medicine, vol. 27, no. 3, pp. 273–282, 2000. View at Google Scholar · View at Scopus
102. M. Henze, J. Schuhmacher, P. Hipp et al., “PET imaging of somatostatin receptors using [⁶⁸GA]DOTA-D-Phe¹-Tyr³-Octreotide: first results in patients with meningiomas,” Journal of Nuclear Medicine, vol. 42, no. 7, pp. 1053–1056, 2001. View at Google Scholar · View at Scopus
103. M. Henze, A. Dimitrakopoulou-Strauss, S. Milker-Zabel et al., “Characterization of ⁶⁸Ga-DOTA-D-Phe¹-Tyr³-octreotide kinetics in patients with meningiomas,” Journal of Nuclear Medicine, vol. 46, no. 5, pp. 763–769, 2005. View at Google Scholar · View at Scopus
104. P. J. Derome, “Surgical management of tumours invading the skull base,” The Canadian Journal of Neurological Sciences, vol. 12, no. 4, pp. 345–347, 1985. View at Google Scholar · View at Scopus
105. G. Guiot and P. Derome, “Apropos of meningiomas “en plaque” of the pterion. Surgical treatment of hyperostotic osseous meningiomas,” Annales de Chirurgie, vol. 20, no. 19, pp. 1109–1127, 1966. View at Google Scholar · View at Scopus
106. B. Gehler, F. Paulsen, M. T. Oksüz et al., “[⁶⁸Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning,” Radiation Oncology, vol. 4, no. 1, article 56, 2009. View at Publisher · View at Google Scholar · View at Scopus
107. F. Nyuyki, M. Plotkin, R. Graf et al., “Potential impact of ⁶⁸Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 310–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
108. D. Thorwarth, G. Henke, A. C. Müller et al., “Simultaneous ⁶⁸Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 1, pp. 277–283, 2011. View at Publisher · View at Google Scholar
109. S. Milker-Zabel, A. Zabel-du Bois, M. Henze et al., “Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [⁶⁸Ga]-DOTATOC-PET,” International Journal of Radiation Oncology, Biology, Physics, vol. 65, no. 1, pp. 222–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
110. W. Becker, “Nuclear medicine goes therapy?” Nuklearmedizin, vol. 38, no. 2, pp. 3–5, 1999. View at Google Scholar · View at Scopus
111. S. M. Larson, J. Tjuvajev, and R. Blasberg, “Triumph over mischance: a role for nuclear medicine in gene therapy,” Journal of Nuclear Medicine, vol. 38, no. 8, pp. 1230–1233, 1997. View at Google Scholar · View at Scopus